These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 38240835)

  • 41. CDK4/6 inhibitors: mechanisms of resistance and potential biomarkers of responsiveness in breast cancer.
    Cetin B; Wabl CA; Gumusay O
    Future Oncol; 2022 Mar; 18(9):1143-1157. PubMed ID: 35137602
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cyclin-dependent kinase 4/6 inhibitors combined with stereotactic ablative radiotherapy in oligometastatic HR-positive/HER2-negative breast cancer patients.
    Kubeczko M; Gabryś D; Krzywon A; Jarząb M
    Br J Radiol; 2024 Oct; 97(1162):1627-1635. PubMed ID: 39120877
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Place in Therapy of Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: A Targeted Literature Review.
    Zhao M; Hanson KA; Zhang Y; Zhou A; Cha-Silva AS
    Target Oncol; 2023 May; 18(3):327-358. PubMed ID: 37074594
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Side effects of CDK4/6 inhibitors in the treatment of HR+/HER2- advanced breast cancer: a systematic review and meta-analysis of randomized controlled trials.
    Yang L; Xue J; Yang Z; Wang M; Yang P; Dong Y; He X; Bao G; Peng S
    Ann Palliat Med; 2021 May; 10(5):5590-5599. PubMed ID: 34107710
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The impact of ethnicity on efficacy and toxicity of cyclin D kinase 4/6 inhibitors in advanced breast cancer: a meta-analysis.
    Lee KWC; Lord S; Finn RS; Lim E; Martin A; Loi S; Lynch J; Friedlander M; Lee CK
    Breast Cancer Res Treat; 2019 Feb; 174(1):271-278. PubMed ID: 30465154
    [TBL] [Abstract][Full Text] [Related]  

  • 46. CDK4/6 inhibitors and endocrine therapy in the treatment of metastatic breast cancer: A real-world and propensity score-adjusted comparison.
    Coutinho-Almeida J; Silva AS; Redondo P; Rodrigues PP; Ferreira A
    Cancer Treat Res Commun; 2024; 40():100818. PubMed ID: 38761788
    [TBL] [Abstract][Full Text] [Related]  

  • 47. HR+, HER2- Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles.
    Sammons SL; Topping DL; Blackwell KL
    Curr Cancer Drug Targets; 2017; 17(7):637-649. PubMed ID: 28359238
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316).
    Futamura M; Nakayama T; Yoshinami T; Oshiro C; Ishihara M; Morita M; Watanabe A; Tanigichi A; Tsukabe M; Shimoda M; Nitta K; Chihara Y; Yasojima H; Ouchi Y; Tokumaru Y; Masuda N
    Breast Cancer; 2023 Nov; 30(6):943-951. PubMed ID: 37486454
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
    Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
    Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Elacestrant in ER+, HER2- Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups.
    Bardia A; Cortés J; Bidard FC; Neven P; Garcia-Sáenz J; Aftimos P; O'Shaughnessy J; Lu J; Tonini G; Scartoni S; Paoli A; Binaschi M; Wasserman T; Kaklamani V
    Clin Cancer Res; 2024 Oct; 30(19):4299-4309. PubMed ID: 39087959
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Optimizing CDK4/6 inhibitors in advanced HR+/HER2- breast cancer: A personalized approach.
    Fontanella C; Giorgi CA; Russo S; Angelini S; Nicolardi L; Giarratano T; Frezzini S; Pestrin M; Palleschi D; Bolzonello S; Parolin V; Haspinger ER; De Rossi C; Greco F; Gerratana L
    Crit Rev Oncol Hematol; 2022 Dec; 180():103848. PubMed ID: 36257536
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis.
    Piezzo M; Chiodini P; Riemma M; Cocco S; Caputo R; Cianniello D; Di Gioia G; Di Lauro V; Rella FD; Fusco G; Iodice G; Nuzzo F; Pacilio C; Pensabene M; De Laurentiis M
    Int J Mol Sci; 2020 Sep; 21(17):. PubMed ID: 32899139
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of PR status on the prognosis of advanced ER-high HER2-negative breast cancer patients receiving CDK4/6 inhibitor combined with endocrine as first-line therapy.
    Jia L; Peng J; Sun N; Chen H; Liu Z; Zhao W; Zhang Q; Li L
    BMC Cancer; 2024 Jul; 24(1):850. PubMed ID: 39020297
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Anti-hormonal maintenance treatment with the CDK4/6 inhibitor ribociclib after 1st line chemotherapy in hormone receptor positive / HER2 negative metastatic breast cancer: A phase II trial (AMICA).
    Decker T; Lüdtke-Heckenkamp K; Melnichuk L; Hirmas N; Lübbe K; Zahn MO; Schmidt M; Denkert C; Lorenz R; Müller V; Zahm DM; Mundhenke C; Bauer S; Thill M; Seropian P; Filmann N; Loibl S
    Breast; 2023 Dec; 72():103575. PubMed ID: 37690320
    [TBL] [Abstract][Full Text] [Related]  

  • 55. CDK4/6 inhibition in low burden and extensive metastatic breast cancer: summary of an
    Awada A; Gligorov J; Jerusalem G; Preusser M; Singer C; Zielinski C
    ESMO Open; 2019; 4(6):e000565. PubMed ID: 31798979
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Targeting CDK4/6 pathways and beyond in breast cancer.
    Ribnikar D; Volovat SR; Cardoso F
    Breast; 2019 Feb; 43():8-17. PubMed ID: 30359883
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
    Finn RS; Crown JP; Lang I; Boer K; Bondarenko IM; Kulyk SO; Ettl J; Patel R; Pinter T; Schmidt M; Shparyk Y; Thummala AR; Voytko NL; Fowst C; Huang X; Kim ST; Randolph S; Slamon DJ
    Lancet Oncol; 2015 Jan; 16(1):25-35. PubMed ID: 25524798
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Endocrine therapy-based treatments in hormone receptor-positive/HER2-negative advanced breast cancer: systematic review and network meta-analysis.
    Brandão M; Maurer C; Ziegelmann PK; Pondé NF; Ferreira A; Martel S; Piccart M; de Azambuja E; Debiasi M; Lambertini M
    ESMO Open; 2020 Aug; 5(4):. PubMed ID: 32847835
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparative Efficacy of CDK4/6 Inhibitors Plus Aromatase Inhibitors Versus Fulvestrant for the First-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer: A Network Meta-Analysis.
    Guo Q; Lin X; Ye L; Xu R; Dai Y; Zhang Y; Chen Q
    Target Oncol; 2019 Apr; 14(2):139-148. PubMed ID: 30941621
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Triglyceride-Glucose Index: A Candidate Prognostic Marker in HR-Positive/HER2-Negative Metastatic Breast Cancer Patients Treated With CDK4/6 Inhibitors.
    Önder T; Ateş Ö; Öner İ; Karaçin C
    Clin Breast Cancer; 2024 Aug; 24(6):519-526. PubMed ID: 38879437
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.